Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.20.8823

Treatment Efficacy and Prognostic Factors for Huge HCC Based on Barcelona Clinic Liver Cancer Staging  

Zhang, Zhi-Ming (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Zhang, Yu-Mei (Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University)
Gao, Sheng (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Yuan, Wei-Ping (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Zhao, Yin-Nong (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Xiang, Bang-De (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Wu, Fei-Xiang (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Wu, Guo-Bin (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Liu, Jian-Yong (Department of Hepatobiliary Surgery, The Affiliated Tumor Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.20, 2014 , pp. 8823-8828 More about this Journal
Abstract
Objective: To explore the most appropriate treatment for patients with hepatocellular cancer (HCC) >10 cm by using the Barcelona Clinic Liver Cancer (BCLC) classification. Materials and Methods: A total of 124 HCC patients undergoing surgery were selected. Disease-free survival (DFS), overall survival (OS) and prognostic factors were respectively assessed. Results: This study showed that the cumulative 1-, 3-, 5-year survival rates were 79.7%, 59.8% and 41.6% in BCLC-A patients, 76.2%, 9.5% and 0% in BCLC-B patients and 44.9%, 0% and 0% in BCLC-C patients, respectively. The 1-, 3-, 5-year DFS rates were 49%, 24.5% and 9.1% in BCLC-A patients, 7.5%, 0% and 0% in BCLC-B patients, respectively. No BCLC-C patients survived 1 year after surgery. Multivariate analysis indicated that hepatitis B surface antigen (HBsAg), vascular invasion, intra-hepatic metastasis, curative resection, tumor rupture and pathologic differentiation were independent prognostic factors. Conclusions: Surgery is effective and safe for patients with HCC >10 cm with sufficient hepatic reserve.
Keywords
Barcelona clinic liver cancer staging; huge hepatocellular carcinoma; hepatectomy; efficacy;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Cheng XP, Zhang ZW (2009). Surgical treatment strategy of large and huge hepatocellular carcinoma. Chin J Operative Proced General Surg, 3, 702-6.
2 Jin YJ, Lee JW, Choi YJ, et al (2014). Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg, 18, 555-61.   DOI
3 Chow KC, Tang CN, Lai EC, et al (2013). Curative treatment for recurrent tumour implantation after ruptured hepatocellular carcinoma. Hong Kong Med J, 19, 82-4.
4 Graf D, Vallbohmer D, Knoefel WT, et al (2014). Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med, 25, 430-7.   DOI   ScienceOn
5 Hironori K, Masaru T, Yuichiro O, et al (2008). Laparoscopyassisted hepatectomy for giant hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech, 18, 127-31.   DOI   ScienceOn
6 Joshita S, Yoshizawa K, Sano K, et al (2010). A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med, 49, 991-4.   DOI
7 Li GH, Hong ZX, Zhang KM (2012). Surgical treatment of huge hepatocellular carcinoma. J Mod Oncol, 20, 1495- 7.
8 Li SH, Guo ZX, Xiao CZ, et al (2013). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63.   과학기술학회마을   DOI   ScienceOn
9 Li SL, Su M, Peng T, et al (2013). Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 14, 217-23.   과학기술학회마을   DOI   ScienceOn
10 Arai T, Akita S, Sakon M, et al (2014). Hepatocellular carcinoma associated with sarcoidosis. Int J Surg Case Rep, 5, 562-5.   DOI   ScienceOn
11 Ren YQ, Han JQ, Cao JB, et al (2012). Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev, 13, 5451-4.   과학기술학회마을   DOI   ScienceOn
12 Bagi CM, Gebhard DF, Andresen CJ (2012). Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models ofhepatocellular carcinoma. Eur J Gastroenterol Hepatol, 24, 563-74.   DOI
13 Maida M, Orlando E, Camma C, et al (2014). Staging systems of hepatocellular carcinoma: areviewofliterature. World J Gastroenterol, 20, 4141-50.   DOI   ScienceOn
14 Que JY, Lin LC, Lin KL, et al (2014). The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol, 9, 120.   DOI   ScienceOn
15 Scaggiante B, Kazemi M, Pozzato G, et al (2014). Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol, 20, 1268-88.   DOI   ScienceOn
16 Shin YJ, Kim MS, Yoo SY, et al (2010). Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori, 96, 65-70.
17 Tsoulfas G, Mekras A, Agorastou P, et al (2012). Surgical treatment for large hepatocellular carcinoma: does size matter? ANZ J Surg, 82, 510-7.   DOI   ScienceOn
18 Yang L, Xu J, Ou D, et al (2013). Hepatectomy for Huge Hepatocellular Carcinoma: Single Institutes Experience. World J Surg, 37, 2189-96.   DOI   ScienceOn
19 Wang ZJ, Wang MQ, Duan F, et al (2013). Clinical application of transcatheter arterial chemoembolization combined with synchronous C-arm cone-beam CT guided radiofrequency ablation in treatment of large hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 1649-54.   과학기술학회마을   DOI   ScienceOn
20 Yang J, Li C, Wen TF, et al (2014). Is hepatectomy for huge hepatocellular carcinoma (${\geq}$ 10cm in diameter) safe and effective? A single-center experience. Asian Pac J Cancer Prev, 15, 7069-77.   과학기술학회마을   DOI   ScienceOn
21 Yang LY, Fang F, Yang H (2010). Surgical resection of solitary huge hepatocellular carcinoma. Chin J Pract Surg, 30, 662-4.
22 Yamashita Y, Taketomi A, Shirabe K, et al (2011). Outcomes of hepatic resection for huge hepatocellularcarcinoma (${\geq}$ 10cm in diameter). J Surg Oncol, 104, 292-8.   DOI   ScienceOn
23 Zhang Y, Zhang WL, Huang DS, et al (2013). Clinical efficacy and prognosis factors for advanced hepatoblastoma in children: a 6-year retrospective study. Asian Pac J Cancer Prev, 14, 4583-9.   과학기술학회마을   DOI   ScienceOn
24 Zhong NB, Lv GM, Chen ZH (2014). Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (${\geq}$ 10 cm)hepatocellular carcinomas: A clinical study. Mol Clin Oncol, 2, 839-844.
25 Zhang ZW, Cheng XP (2008). Techniques for large hepatic resection. J Hepatobil Surg, 16, 6-7.